Yahoo
    NasdaqCM - Nasdaq Real Time Price USD

    Corbus Pharmaceuticals Holdings, Inc. (CRBP)

    3.0700 +0.2100 (+7.34%)
    At close: November 6 at 4:00:01 PM EST
    3.0700 0.0000 (0.00%)
    After hours: November 6 at 4:00:08 PM EST
    Trade CRBP on Coinbase
    Chart Range Bar
    Advanced Chart
    AlphaSpace Chart
    Loading chart for CRBP
    • Previous Close 2.8600
    • Open 2.9300
    • Bid 2.5800 x 100
    • Ask 3.4800 x 100
    • Day's Range 2.9100 - 3.1250
    • 52 Week Range 2.8100 - 12.8810
    • Volume 684,164
    • Avg. Volume 1,055,185
    • Market Cap (intraday) 59.378M
    • Beta (5Y Monthly) 2.79
    • PE Ratio (TTM) --
    • EPS (TTM) -6.1100
    • Earnings Date (est.) Nov 16, 2026
    • Forward Dividend & Yield -- (0.00%)
    • 1y Target Est 34.89
    • Moby Rating Bear

    Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.

    www.corbuspharma.com

    36

    Full Time Employees

    December 31

    Fiscal Year Ends

    Healthcare

    Sector

    Biotechnology

    Industry

    More about Corbus Pharmaceuticals Holdings, Inc.

    Recent News

    View More
    View More

    Performance Overview

    Trailing total returns as of 11/6/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

    YTD Return

    CRBP
    62.29%
    S&P 500 (^GSPC)
    7.76%

    1-Year Return

    CRBP
    70.59%
    S&P 500 (^GSPC)
    9.77%

    3-Year Return

    CRBP
    39.09%
    S&P 500 (^GSPC)
    68.96%

    5-Year Return

    CRBP
    90.06%
    S&P 500 (^GSPC)
    57.04%

    Earnings Trends

    View More

    Earnings Per Share

    GAAP
    Normalized
    GAAP
    Normalized

    Revenue vs. Earnings

    Annual
    Quarterly
    Annual
    Quarterly
    Q2 FY26
    Revenue --
    Earnings -35.04M
    Profit Margin 0.00%

    Q3

    FY25

    Q4

    FY25

    Q1

    FY26

    Q2

    FY26

    -30M
    -20M
    -10M
    0
    0.0%
    View More

    Analyst Insights

    View More

    Analyst Price Targets

    24.00
    34.89 Average
    3.0700 Current
    48.00 High

    Analyst Recommendations

    • Strong Buy
    • Buy
    • Hold
    • Underperform
    • Sell

    Latest Rating

    Date 9/14/2026
    Analyst HC Wainwright & Co.
    Rating Action Reiterates
    Rating Buy
    Price Action Maintains
    Price Target 35 -> 35
    View More

    Statistics

    View More

    Valuation Measures

    Annual

    • Market Cap

    • Enterprise Value

    • Trailing P/E

    • Forward P/E

    • PEG Ratio (current)

    • Price/Sales (ttm)

    • Price/Book (mrq)

    • Enterprise Value/Revenue

    • Enterprise Value/EBITDA

    Financial Highlights

    Profitability and Income Statement

    • Profit Margin

      0.00%

    • Return on Assets (ttm)

      -53.00%

    • Return on Equity (ttm)

      -95.58%

    • Revenue (ttm)

      --

    • Net Income Avi to Common (ttm)

      -101.9M

    • Diluted EPS (ttm)

      -6.1100

    Balance Sheet and Cash Flow

    • Total Cash (mrq)

      117.94M

    • Total Debt/Equity (mrq)

      4.17%

    • Levered Free Cash Flow (ttm)

      -49.62M

    View More

    Company Insights

    Research Reports

    View More
    View More

    People Also Watch

    TVRD Tvardi Therapeutics, Inc.
    0.9578 +12.20%
    CANN Trees Corporation
    0.0162 -0.61%
    ITRMF Iterum Therapeutics plc
    0.0000 0.00%
    JAGX Jaguar Health, Inc.
    0.4043 -6.17%
    CRON Cronos Group Inc.
    3.6100 -2.96%
    Mobilize your Website
    View Site in Mobile | Classic
    Share by: